HEIDELBERG, Germany–(BUSINESS WIRE)– #ESMO2026–Hummingbird Diagnostics GmbH, a pioneer in blood-based small RNA biomarker discovery and assay development, today announced new clinical data demonstrating the ability of small RNA to enable adaptive treatment strategies in lung cancer patients. The results were presented at the ESMO Congress 2026 in Madrid, Spain. The work involved collaborations with LungenClinic Grosshansdorf, Germany, and University Hospital and Polyclinic F.D. Roosevelt in Banská Bystr

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.